logo

NeuroHealing Pharmaceuticals Inc.

Internet:
info@neurohealing.com
http://www.neurohealing.com

 spacer Company Information:
NeuroHealing Pharmaceuticals Inc.
50 Undine Road
Suite #1
Newton, MA 02135
USA
Ph. 617.331.4111
Fx. 617.777.1267

RSS Feed
Media Contacts:
Daniel Katzman
President
617.331.4111
info@NeuroHealing.com

NeuroHealing develops and commercializes novel therapeutics based on new formulation strategies to treat the needs of post-acute neurorehabilitation patients, including disorders such as traumatic brain injury, stroke, Parkinson�s disease and other motor neuron diseases.

Recent Company Headlines
08/26/11  ›The Michael J. Fox Foundation Grants Second Award to NeuroHealing for Clinical Trial of NH004 for Sialorrhea Control in Parkinson's Disease
05/23/11  ›NeuroHealing Announces Orphan Drug Designation in Europe for NH001 for the Treatment of Patients Following a Moderate or Severe Traumatic Brain Injury
05/16/11  ›NeuroHealing Announces Strategic Master Services and Investment Agreement With Cato BioVentures
05/09/11  ›NeuroHealing Announces Issuance of U.S. Patent for Brain Injury Treatment
12/10/10  ›Positive Results of Phase II Clinical Study for the Treatment of Sialorrhea Presented at Parkinson' Disease Congress by NeuroHealing Pharmaceuticals
11/03/10  ›NeuroHealing Awarded Qualified Therapeutic Development Project Grant
08/21/09  ›NeuroHealing Announces Formation Of Medical Advisory Board For NH02D Program
04/13/09  ›NeuroHealing to Present Data on NH02D Premature Ejaculation Drug at AUA Meeting
02/02/09  ›NeuroHealing Appoints David Gwynne, Vice President Business Development
09/24/08  ›Oct. 6-7: NeuroHealing Pharmaceuticals To Present At Drug Repositioning Summit In Boston
08/11/08  ›Industry Leaders Select NeuroHealing's NH001 Among Top Ten Most Promising Neuroscience Projects Available For Partnering
07/22/08  ›Life Science Angels Makes Additional Investment In NeuroHealing Pharmaceuticals
02/19/08  ›NeuroHealing Pharmaceuticals initiates Phase II Clinical Trial of NH004 for Sialorrhea Control in Parkinson's Disease Patients
01/03/08  ›NeuroHealing Pharmaceuticals Appoints Burt Adelman, M.D., To Board Of Directors
12/13/07  ›The Michael J. Fox Foundation Awards Funding To NeuroHealing Pharmaceuticals Researchers for a Phase II Clinical Trial of NH004 for Sialorrhea Control in Parkinson's Disease Patients
03/12/07  ›NeuroHealing Pharmaceuticals Presents Clinical Data For NH001 In Coma Recovery At The American Society For Experimental NeuroTherapeutics Annual Meeting
09/12/06  ›NeuroHealing Pharmaceuticals CEO, Neal Farber, To Speak At The Dow Jones VentureWire Health Care Innovations 2006 Conference, The Biotech & Life Sciences Global Venture Congress 2006, And The Life Sciences Venture Summit 2006
05/25/06  ›NeuroHealing Receives FDA Orphan Drug Designation For NH001 For The Treatment Of Patients In A Vegetative State Or Minimally Conscious State Following Brain Injury
11/03/05  ›NeuroHealing Pharmaceuticals To Present At Rodman & Renshaw Techvest Seventh Annual Healthcare Conference, Nov. 8
08/31/05  ›NeuroHealing Pharmaceuticals Announces IND Submission For NH001 To Improve The Outcome Of Patients In A Vegetative State Following A Traumatic Brain Injury
12/08/04  ›NeuroHealing Commences Clinical Trial Of NH001 For Coma Patients

Media Items

This company has no media releases.

Recent Reports and Filings
This company has no recent filings.